Stock Events

Stock Events

Kodiak Sciences 

$35.70
77
-$0.66-1.82% 18:22 Today

Statistics

Day High
36.62
Day Low
35.23
52W High
47.84
52W Low
8.55
Volume
325,540
Avg. Volume
689,560
Mkt Cap
2.24B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.16
-1.05
-0.95
-0.84
Expected EPS
-1.013067
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-229.97MNet Income

Analyst Ratings

66.25Average Price Target
The highest estimate is 80.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KOD. It's not an investment recommendation.
Amazon
16
AMZN
Apple
15
AAPL
Tesla
15
TSLA
Walmart
15
WMT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes directly with Kodiak Sciences in the development of treatments for retinal diseases, including age-related macular degeneration.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO Inc. is a competitor because it also focuses on gene therapy for retinal diseases, a key area of focus for Kodiak Sciences.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies, through its eye health division, competes in the broader ophthalmology market, impacting Kodiak Sciences' market share.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is a major pharmaceutical company with a strong presence in the ophthalmology sector, including treatments for conditions that Kodiak Sciences targets.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, after acquiring Allergan, has become a significant player in the eye care market, competing with Kodiak Sciences in several areas.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc has investments in healthcare treatments that span a wide range, including ophthalmology, indirectly competing with Kodiak Sciences.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc., as a large pharmaceutical company, has interests in developing treatments for various diseases, including those in the eye care segment, posing competition to Kodiak Sciences.

About

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Show more...
CEO
Victor Perlroth
Employees
124
Country
United States
ISIN
US50015M1099
WKN
000A2N6P0

Listings

STU
DE
K27.STU
MU
DE
K27.MU
XNAS
US
KOD
BOATS
BOATS
KOD.BOATS

0 Comments

Share your thoughts

FAQ

What is Kodiak Sciences stock price today?▼
The current price of KOD is $35.70 USD — it has decreased by -1.82% in the past 24 hours. Watch Kodiak Sciences stock price performance more closely on the chart.
What is Kodiak Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kodiak Sciences stocks are traded under the ticker KOD.
Is Kodiak Sciences stock price growing?▼
KOD stock has fallen by -5.65% compared to the previous week, the month change is a -17.02% fall, over the last year Kodiak Sciences has showed a +316.26% increase.
What is Kodiak Sciences market cap?▼
Today Kodiak Sciences has the market capitalization of 2.24B
When is the next Kodiak Sciences earnings date?▼
Kodiak Sciences is going to release the next earnings report on November 12, 2026.
What were Kodiak Sciences earnings last quarter?▼
KOD earnings for the last quarter are -1.05 USD per share, whereas the estimation was -0.96 USD resulting in a -9.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kodiak Sciences revenue for the last year?▼
Kodiak Sciences revenue for the last year amounts to 0 USD.
What is Kodiak Sciences net income for the last year?▼
KOD net income for the last year is -229.97M USD.
How many employees does Kodiak Sciences have?▼
As of September 04, 2026, the company has 124 employees.
In which sector is Kodiak Sciences located?▼
Kodiak Sciences operates in the Health & Wellness sector.
When did Kodiak Sciences complete a stock split?▼
Kodiak Sciences has not had any recent stock splits.
Where is Kodiak Sciences headquartered?▼
Kodiak Sciences is headquartered in PALO ALTO, United States.